Urinary-Tract Stones Resulting from the Excretion of Oxypurinol
- 20 March 1975
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 292 (12) , 626-627
- https://doi.org/10.1056/nejm197503202921208
Abstract
COMPOUNDS that inhibit the enzyme, xanthine oxidase, are useful in the treatment of disorders of purine metabolism. They are of particular value in disorders resulting from the overproduction of uric acid. Xanthine oxidase is inhibited by both allopurinol (4-hydroxypyrazolo [3,4-d] pyrimidine), an analogue of hypoxanthine, and oxypurinol (4,6-dihydroxypyrazolo [3,4-d] pyrimidine), which is an analogue of xanthine. Xanthine oxidase catalyzes the conversion of hypoxanthine to xanthine to uric acid. It also catalyzes the conversion of allopurinol to oxypurinol. A major percentage of administered allopurinol is rapidly oxidized to oxypurinol.1 After the administration of a xanthine oxidase inhibitor such as allopurinol or . . .Keywords
This publication has 8 references indexed in Scilit:
- Progressive Seizures With Hyperuricosuria Reversed by AllopurinolArchives of Neurology, 1974
- Nephropathy, xanthinuria, and orotic aciduria complicating Burkitt's lymphoma treated with chemotherapy and allopurinolMetabolism, 1972
- Xanthine Nephropathy in a Patient with Lymphosarcoma Treated with AllopurinolNew England Journal of Medicine, 1970
- Urinary Xanthine Stones-a Rare Complication of Allopurinol TherapyNew England Journal of Medicine, 1969
- Quantitation of oxypurines and allopurinol metabolites in biological fluids by cation-exchange chromatographyAnalytical Biochemistry, 1969
- Excretion of Hypoxanthine and Xanthine in a Genetic Disease of Purine MetabolismNature, 1967
- Augmentation of the incorporation of hypoxanthine into nucleic acids by the administration of an inhibitor of xanthine oxidaseBiochimica et Biophysica Acta, 1963